Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 7, 1999, Pages 1744-1750

  Lentz, Steven R ^a   Fernández, José A ^b   Griffin, John H ^b   Piegors, Donald J ^a   Erger, Rochelle A ^a   Malinow, M René ^c   Heistad, Donald D ^a  

^a UNIVERSITY OF IOWA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Cholesterol; Homocysteine; Protein C; Thrombomodulin

Indexed keywords

HOMOCYSTEINE; PROTEIN C; THROMBIN;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; HYPERHOMOCYSTEINEMIA; MONKEY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS; VITAMIN INTAKE;

EID: 0345711683     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.7.1744     Document Type: Article

References (33)

1. Griffin JH. Blood coagulation: the thrombin paradox. Nature. 1995;378: 337-338.
2. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J. 1995;9:946-955.
3. Lentz SR, Sadler JE. The molecular basis of thrombomodulin function. In: Giddings JC, ed. Thrombin, Thrombomodulin, and the Control of Hemostasis. Austin, Tex: RR Landes Co; 1994;1:91-120.
4. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369:64-67.
5. Greengard JS, Sun X, Xu X, Fernández JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 1994;343:1361-1362.
6. Zöller B, Hillarp A, Berntorp E, Dahlbäck B. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annu Rev Med. 1997;48:45-58.
7. Fisher M, Fernández JA, Ameriso SF, Xie DC, Gruber A, Paganini-Hill A, Griffin JH. Activated protein C resistance in ischemic stroke not due to factor V arginine (506)→glutamine mutation. Stroke. 1996;27: 1163-1166.
8. van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PTVM, Hofman A, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med. 1996;125:265-269.
9. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 1996;98:24-29.
10. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274: 1049-1057.
11. Lentz SR, Malinow MR, Piegors DJ, Bhopatkar-Teredesai M, Farad FM, Heistad DD. Consequences of hyperhomocyst(e)inemia on vascular function in atherosclerotic monkeys. Arterioscler Thromb Vasc Biol. 1997;17:2930-2934.
12. Fink LM, Eidt JF, Johnson K, Cook JM, Cook CD, Morser J, Marlar R, Collins CL, Schaefer R, Xie S-S, Hsu S-M, Hsu P-L. Thrombomodulin activity and localization. Int J Dev Biol. 1993;37:221-226.
13. Okajima K, Koga S, Kaji M, Inoue M, Nakagaki T, Funatsu A, Okabe H, Takatsuki K, Aoki N. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost. 1990;63:48-53.
14. Armstrong ML, Heistad DD, Marcus ML, Megan MB, Piegors DJ. Structural and hemodynamic responses of peripheral arteries of macaque monkeys to atherogenic diet. Arteriosclerosis. 1985;5:336-346.
15. Gruber A, Griffin JH, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood. 1989;73:639-642.
16. Gruber A, Hanson SR, Kelly AB, Yan SB, Bang NU, Griffin JH, Harker LA. Inhibition of thrombus formation by activated protein C in a primate model of arterial thrombosis. Circulation. 1990;82:578-585.
17. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood. 1992;79:2340-2348.
18. Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest. 1993;92:2003-2012.
19. von Clauss A. Gerinnungsphysiologische Schnellmethode zur bestimmung des fibrinogens. Acta Haematol. 1957;17:237.
20. Tripodi A, Negri B, Bertina RM, Mannucci PM. Screening for the FV-Q(506) mutation: evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost. 1997;77:436-439.
21. Elisen MG, Maseland MH, Church FC, Bouma BN, Meijers JC. Role of the A+ helix in heparin binding to protein C inhibitor. Thromb Haemost. 1996;75:760-766.
22. Malinow MR, Kang SS, Taylor LM, Wong PWK, Coull B, Inahara T, Mukerjee D, Sexton G, Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989; 79:1180-1188.
23. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)inemia in daily practice: levels in coronary artery disease. Coron Artery Dis. 1990;1:215-220.
24. Lauer RM, Lee J, Clarke WR. Factors affecting the relationship between childhood and adult cholesterol levels: the Muscatine study. Pediatrics. 1988;82:309-318.
25. Rezaie AR, Cooper ST, Church FC, Esmon CT. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem. 1995;270:25336-25339.
26. Lollar P, Owen WG. Clearance of thrombin from the circulation in rabbits by high-affinity binding sites on endothelium. J Clin Invest. 1980;66: 1222-1230.
27. Gibbs CS, Coutre SE, Tsiang M, Li WX, Jain AK, Dunn KE, Law VS, Mao CT, Matsumura SY, Mejza SJ, Paborsky LR, Leung LLK. Conversion of thrombin into an anticoagulant by protein engineering. Nature. 1995;378:413-416.
28. Benzuly KH, Padgett RC, Kaul S, Piegors DJ, Armstrong ML, Heistad DD. Functional improvement precedes structural regression of atherosclerosis. Circulation. 1994;89:1810-1818.
29. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci U S A. 1996; 93:10212-10216.
30. Laszik Z, Mitro A, Taylor FB, Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation. 1997; 96:3633-3640.
31. Kojima K, Fernández JA, Banka CL, Curtiss L, Griffin JH. High density lipoprotein enhancement of the antithrombotic protein C pathway. [Abstract.] Blood. 1996;88:523a.
32. Rota S, Mcwilliam NA, Baglin TP, Byrne CD. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood. 1998;91: 508-515.
33. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 1991;88:1906-1914.